Societe Generale Shares Jump to 2008 High on Upbeat Outlook, Higher Returns
France's third largest lender by market capitalization benefited from a continued rebound in its domestic retail-banking operations and cost controls, which helped its profit for the second quarter rise sharply.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Tensive appoints medical device veteran Bill Hunter Chairman as its bioresorbable scaffold for breast reconstruction after cancer approaches market
Has more than 30 years of experience bringing innovations to market, including one of the world's first drug-eluting coronary stents at Angiotech Pharma Appointment adds world-class capabilities to Tensive as the company approaches pivotal clinical trial milestones Pivotal trial may enable European and U.S. commercialization of Tensive's innovative bioresorbable REGENERA™ and SOFTAG™ devices for breast reconstruction and tissue marking Tensive published positive first impressions from pivotal trial in April, and from first-in-human trial in 2023 Milan, Italy – August 5, 2025 – Tensive S.r.l, a clinical-stage advanced biomaterials medical device company, and the developer of REGENERA™ and SOFTAG™ bioresorbable scaffolds for breast reconstruction and tissue marking, has appointed Bill Hunter, MD, as Chairman of its Board of Directors. Dr. Hunter brings more than 30 years of leadership in the medical technology and life sciences sectors. His appointment reflects Tensive's focus on strengthening its governance and expanding its global network as it accelerates toward pivotal clinical milestones and commercialization in the U.S. and Europe. Dr. Hunter is the founder and CEO of Canary Medical, a medical data company developing implantable sensor technology. Previously, he founded Angiotech Pharmaceuticals, where he led the development of one of the world's first drug-eluting coronary stents, a multi-billion-dollar innovation that transformed interventional cardiology. 'It's a great honor and validation of the medical potential of Tensive's advanced biomaterials that Bill has accepted to lead our board of directors. His track record of successfully guiding pioneering technologies from concept to commercialization is unmatched,' said Sanjay Kakkar, Chief Executive Officer of Tensive. 'Bill's strategic insights and industry perspectives will be crucial advantages as we complete registrational studies and advance our first device into regulatory processes for marketing approval and commercialization in the U.S. and Europe.' Tensive's innovative polymeric bioresorbable scaffolds allow a natural, non-invasive, permanent and safe solution for breast reconstruction during lumpectomy. In addition, they enable precision tissue marking, demarcating the affected area to direct more targeted radiotherapy and improve imaging accuracy during surveillance and follow-up. 'I am truly excited to join Tensive at such a pivotal moment in its journey,' said Bill Hunter, MD, Chairman of the Tensive Board of Directors. 'In addition to being impressed by the leadership, I became convinced that this was an exceptional opportunity after reviewing the recently published interim data from the ongoing pivotal study of REGENERA™, as well as the excellent long-term follow-up data from the first-in-human clinical trial. The enthusiasm expressed by the key opinion leaders involved with the clinical studies further confirmed my impression of the data. I look forward to supporting Sanjay and his experienced team at Tensive as they bring REGENERA™ and SOFTAG™ to the market.' REGENERA™ / SOFTAG™ advanced biomaterial is a bioresorbable implant designed to be placed during lumpectomy surgery. The bioresorbable medical device is gradually absorbed by the body and enables the patient's own tissue to regrow in the area it fills. The result is breast restoration composed of natural tissue that preserves the patient's original breast shape and feel, yet is clearly differentiated from surrounding tissues on imaging, supporting more targeted delivery of radiotherapy and more accurate monitoring for potential recurrence. The biomaterial used in REGENERA™ and SOFTAG™ resembles a sponge with a fine scaffold matrix; its placement during the lumpectomy surgery is a one-step, minimally invasive, rapid and easy-to-adopt procedure. Currently, patients undergoing benign and malignant lumpectomy do not typically receive cosmetic intervention to prevent breast disfigurement, which can be psychologically devastating. Of the 2.1 million lumpectomies performed worldwide each year, 1.9 million are not reconstructed, constituting a sizeable unmet clinical need [1]. Despite the psychological impact of breast disfigurement following lumpectomy, more common cosmetic surgery options are rarely used, because they entail invasive and complex procedures that often fail to achieve the desired outcome. Preliminary data from the first 16 patients in Tensive's ongoing multi-center pivotal trial in 94 patients undergoing malignant lumpectomy were published in Updates in Surgery in April 2025, with investigators writing: 'In conclusion, we are convinced that REGENERA™ could represent a great innovation in breast oncological surgery, representing a possible alternative to volume replacement with faster operative time, faster recovery, less morbidity, and good patient satisfaction [2].' These results followed the publication in Breast Cancer in 2023 of six-month follow-up data from five patients in a first-in-human trial that demonstrated positive outcomes in terms of both safety and performance, leading the clinical investigators who authored the paper to conclude that the data were 'paving the way to an innovative approach with a potential remarkable impact on clinical application of tissue engineering [3].' [1] Analysis based on estimates from the International Society of Aesthetic Plastic Surgery (ISAPS), Breast Cancer Research Foundation (BCRF), the American College of Surgeons (ACS), the World Health Organization (WHO) and Global Market Insights.[2] A.V.E. Lisa et al. Updates in Surgery Apr 2025. Mariniello et al. Breast Cancer 2023. S.r.l. ( is a clinical-stage advanced biomaterials medical device company developing bioresorbable polymeric scaffolds for breast reconstruction and tissue marking. Its patented REGENERA™ biomimetic scaffold is designed to allow regeneration of a patient's own breast tissue to create natural, safe, and lasting reconstruction for patients recovering from lumpectomy or undergoing cosmetic procedures, while its SOFTAG™ precision tissue marking device enables more targeted delivery of radiotherapy and increases the accuracy of surveillance and follow-up. Tensive's mission is to improve clinical outcomes and the quality of life for women worldwide through accessible, innovative, and sustainable solutions. For more information please contact: Tensive Srl Cohesion Bureau media@ Italian and international media & investorsGiovanni Ca' Zorzitensive@ 7 8467 0727 Attachment 20250805 Tensive PR Bill Hunter appointment (final)Error in retrieving data Sign in to access your portfolio Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
E-Invoicing: Quadient Reaches Key Milestone as Serensia Successfully Passes French Tax Authority Testing
E-Invoicing: Quadient Reaches Key Milestone as Serensia Successfully Passes French Tax Authority Testing Quadient (Euronext Paris: QDT), a global intelligent automation platform enabling secure and professional business connections, announced today that Serensia, its recent acquisition in the digital segment, has successfully completed interoperability testing in live conditions as part of France's phased rollout of mandatory e-invoicing. Serensia, a certified French e-invoicing platform connected to the Peppol network, was selected by the French Public Finance Department, along with two other platforms, formerly designated as Partner Dematerialization Platforms (PDP) and now referred to as Certified Platforms, to participate in the first round of interoperability testing. Conducted under real-world conditions, the tests validated the public directory's interaction with other platforms and the government's data hub. Beyond demonstrating technical capabilities, the initiative reflects a broader commitment to strengthening collaboration between private-sector players and public authorities. The results confirm Serensia's robustness, reliability and compliance, marking a major step forward in Quadient's readiness and reaffirming its ability to support businesses in meeting the requirements of the e-invoicing reform. 'The French Public Finance Department's selection of Serensia for the initial round of real-world testing speaks to the strength of the solution,' said Geoffrey Godet, CEO of Quadient. 'Its successful compliance testing validates the strategic choices we've made, particularly the acquisition of Serensia, which now positions Quadient at the forefront of the reform's implementation across all French companies. Our message to businesses is clear: transitioning to e-invoicing requires preparation, and Quadient is more ready than ever to support them with a proven, reliable and compliant solution.' As of July 1, the central directory listing all VAT-registered businesses has gone live. Quadient is already able to register clients who have granted it a mandate, in accordance with the government-defined process. Through its subsidiary Serensia or its own certified platform, the company is preparing for its final registration, expected in fall 2025. This will enable it to fully support large enterprises, mid-sized companies, SMEs and accounting firms in the digital transition mandated by the reform. To learn more about Quadient's invoicing and payment solutions, visit: About Quadient®Quadient is a global automation platform powering secure and sustainable business connections through digital and physical channels. Quadient supports businesses of all sizes in their digital transformation and growth journey, unlocking operational efficiency and creating meaningful customer experiences. Listed in compartment B of Euronext Paris (QDT) and part of the CAC® Mid & Small and EnterNext® Tech 40 indices, Quadient shares are eligible for PEA-PME investing. For more information about Quadient, visit Media Contacts Joe Scolaro, QuadientGlobal Press Relations Manager+1 203-301-3673jscolaro@ Kiley Ribordy, Walker SandsSenior PR Directorquadientpr@ Attachment PR Quadient Serensia France tests DGFiP - EN
Yahoo
20 minutes ago
- Yahoo
BP to review assets and costs as profit beats expectations
By Shadia Nasralla LONDON (Reuters) -BP will review its portfolio of assets and consider further cost cuts as part of a drive to do better for shareholders, the oil major said on Tuesday, as it reported a second-quarter profit that easily beat expectations. Under pressure to improve profitability, not least from activist investor Elliott, CEO Murray Auchincloss earlier this year announced plans to sell $20 billion of assets through to 2027, reduce spending and share buybacks, and cut costs. On Tuesday, he signalled further action might follow, without giving details. "We will conduct a thorough review of our portfolio of businesses to ensure we are maximizing shareholder value moving forward – allocating capital effectively. We are also initiating a further cost review," Auchincloss said. "BP can and will do better for its investors.' BP has a target to cut costs by $4-$5 billion from 2023 levels by the end of 2027, of which it has achieved $1.7 billion, it said. The company posted a second-quarter underlying replacement cost profit, or adjusted net income, of $2.4 billion, down 14% from last year's $2.8 billion, but easily beating the average $1.8 billion in a company-provided poll of analysts. Its quarterly dividend will rise to 8.32 cents from 8 cents in the first quarter and it will keep the pace of its share buyback programme, making a further $750 million of purchases by the time of its third-quarter results, it said. BP's shares have markedly lagged peers since its 2020 foray into renewables under previous CEO Bernard Looney. Since Auchincloss's strategy revamp in February, BP's shares have lost around 3.5%, compared with rises of around 2.4% for rivals Shell and Exxon, as of Monday.
